Appeal No. 1995-4273
Application No. 08/046,364
1. A composition comprising a microbead coupled with a plurality of binding
molecules which lack Fc portions and which are specific for CD2, CD3 or other T cell
receptor-linked components, CD4, CD5, or CD8.
5. A composition of claim 1, wherein the microbead is hydrophilic, stable, and
nonimmunogenic in humans, and resistant to hydrolysis in human body fluids.
6. A composition of claim 1, wherein the microbead is about 1 to 10 µm in
diameter.
7. A composition of claim 1, wherein the microbead is made by cross-linking
agarose or dextran.
9. A composition of claim 1, wherein the binding molecule is selected from the
group consisting of Fv, Fab, and F(ab’) of antibodies.
2
The references relied on by the examiner are:
Goers et al. (Goers) 4,867,973 Sep. 19, 1989
J.M. Williams, et al. (Williams), “The Events of Primary T Cell Activation Can Be Staged by
Use of Sepharose-Bound Anti-T3 (64.1) Monoclonal Antibody and Purified Interleukin 1,”
Journal of Immunology, Vol. 135, No. 4, (1985), pp. 2249-2255.
T. Geppert, et al. (Geppert), “Accessory Cell Independent Proliferation of Human T4 Cells
Stimulated by Immobilized Monoclonal Antibodies to CD3,” Journal of Immunology, Vol.
138, No. 6, (1987), pp. 1660-1666.
Makinen, et al. (Makinen), Journal of Biological Chemistry, Vol. 264, (1989), pp. 3325-
3334.
Roitt, Immunology, Gower Medical Publishing (1995), page 8.7, figure 8.19.
Claims 1, 5 through 7, and 9 stand rejected under 35 U.S.C. § 103. As evidence of
obviousness, the examiner relies on Williams, Geppert, Makinen, Goers and Roitt.
2
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: November 3, 2007